B
ANTH

Bailard’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Bailard’s Portfolio ANTH Stock Details ANTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-22,000
Closed -$708K – 257
2013
Q3 		$708K Sell
22,000
-8,232
-27% -$255K 0.13% 126
2013
Q2 		$896K Buy
+30,232
New +$1.13M 0.16% 112

Other funds holding ANTH

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

Bailard's ANTH Position: Q4 2013 in Review

Bailard sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q4 2013, closing a stake of 22,000 shares — an estimated $708K sold.

Bailard first reported a position in ANTH in Q2 2013 and held it in 2 quarters. The position peaked at $896K in Q2 2013. 33 funds tracked by Wall St. Rank hold ANTH as of Q4 2013.

  • Bailard reported no remaining Anthera Pharmaceuticals, Inc. position as of Q4 2013 after selling out during the quarter.
  • Bailard sold 22,000 Anthera Pharmaceuticals, Inc. shares in Q4 2013, an estimated $708K.
  • Bailard first reported a position in Anthera Pharmaceuticals, Inc. in Q2 2013 and held it in 2 quarters.
  • Bailard's Anthera Pharmaceuticals, Inc. position peaked at $896K in Q2 2013.
  • 33 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q4 2013.

Based on Bailard's 13F filing for Q4 2013, filed 28 Jan 2014.